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The present study was aimed to evaluate the protective eﬀect of hesperidin against immobilization-stress-induced alterations in
biochemical,behavioral,andmitochondrialfunctionsinmice.Inmanyinstancesneuroscientistshavereportedthatacuteimmobi-
lization stress for 6h resulted in anxiety and impaired locomotor activity due to excess oxidative-nitrergic stress, depletion of anti-
oxidant defense mechanisms, and mitochondrial dysfunction in animals. In the present study, 6h of acute immobilization stress
had signiﬁcantly altered the behavioral (anxiety and memory) and biochemical parameters coupled with mitochondrial dys-
function in Swiss albino mice. Fourteen days of pretreatment with Hesperidin (50 and 100mg/kg, p.o.) signiﬁcantly and dose-
dependently inhibited the behavioral and biochemical alterations and mitochondrial dysfunction caused by acute immobilization
stress.Furthermore,pre-treatment of l-arginine(50mg/kg,i.p.),anitricoxideprecursor,reversedtheprotectiveeﬀectofHesperi-
din (50 and 100mg/kg) (P<0.05). In contrast, pretreatment of l-NAME (5mg/kg, i.p.), a nitric oxide synthase inhibitor, poten-
tiated the protective eﬀect of Hesperidin (P<0.05). These results suggest the possible involvement of nitrergic pathway in the pro-
tective eﬀect Hesperidin against immobilization-stress-induced behavioral, biochemical, and mitochondrial dysfunction in mice.
1.Introduction
Stress is a very crucial factor in the maintenance of
health and disease [1]. Stress induces changes in emotional
behavior and anxiety like state, which are associated with
oxidative damage, that is, free radical damage [2, 3]. Acute
immobilization stress triggers numerous cellular cascades
that lead to increase in ROS production [4]. Because of the
brain high oxygen consumption, abundant lipid content,
and relative paucity of antioxidant enzymes, the central
nervous system is highly vulnerable to free radical damage
[5]. Immobilization stress has also been reported to induce
2-3-fold higher rise of plasma cortisol level; increased
cortisol level has been linked with anxiety-like behavior
[6, 7]. It is been reported that stress triggers the motor
alteration in diﬀerent animal models and central nucleus of
amygdala is important in modulating aﬀective response to
stress [8–10].
Naturalproductssuchasbioﬂavonoidspossessverygood
antioxidant property [11] and inhibit lipid peroxidation in
biological membranes [12]. Hesperidin is a such natural bio-
ﬂavonoid that possesses very good antioxidant property [11]
and it has been proved to be very eﬀective in various neuro-
behavioral diseases [11, 12].
With this background, the present study was designed to
investigate the possible neuroprotective eﬀect of Hesperidin
against acute immobilization-stress-induced anxiety-like be-
havior and associated oxidative damage in mice. The func-
tional interaction of Hesperidin with nitrergic signaling was
investigated using nitric oxide precursor, l-arginine, and
nonselective nitric oxide synthase inhibitor, N (G)-nitro-l-
arginine methyl ester (l-NAME).2 ISRN Pharmacology
2.MaterialsandMethods
2.1. Drugs and Chemicals. Hesperidin, l-arginine, and l-
NAME were purchased from Sigma Aldrich (Bangalore); all
other drugs and chemicals used for the study were of analyt-
ical grade and purchase from local ﬁrms.
2.2. Animals. Male Swiss albino mice weighing 20–25g were
purchased from Bioneeds Preclinical Services, Nelamangala,
Bangalore. They were housed under standard laboratory
conditions and maintained on 12h light/dark cycle and had
free access to food and water. Animals were acclimatized
to laboratory conditions before the experiment. Each group
consists of 10 animals each. All the experiments were carried
out between 9:00 am and 17:00 pm. The experimental pro-
tocols were approved by Institutional Animal Ethics Com-
mittee of PES College of Pharmacy, Bangalore, India (no.
PESCP/IAEC/06/2006-07) and conducted according to the
committee for the purpose of control and supervision of
experimentation on animals (CPCSEA) guidelines for the
use and care of experimental animals.
2.3. Treatment Schedule. The suspension of Hesperidin in
0.5% CMC (carboxy methyl cellulose) in distilled water, l-
NAME, and l-arginine in normal saline was freshly prepared
and administered 10min before Hesperidin treatment (50
and 100mg/kg/day, p.o.). All the treatments were given once
daily for two weeks and animals were subjected to immobi-
lization stress on the 15th day (Figure 1).
2.4. Immobilization Stress. On the 15th day all the animals
(except na¨ ıve) were immobilized for 6h by taping all the four
limbs on a board, after putting them on their backs using
zinc oxide hospital tape. Release was aﬀected by unraveling
the tape after moistening with acetone in order to minimize
pain or discomfort. In unstressed group, the mice were kept
in animal cage with soft bedding in the experimental room
[13].
2.5. Behavioral Assessments
2.5.1. Measurement of Locomotor Activity. Animals were kept
in actophotometer for 3 minutes for acclimatization, fol-
lowed by 5 minutes of actual recording. The apparatus was
placed in a dark, light-sound-attenuated and ventilated test-
ingroom.Eachanimalwasobservedoveraperiodof5minin
a square (30cm) closed arena equipped with infrared-light-
sensitive photocells using digital photoactometer and values
were expressed as counts per 5min [14, 15].
2.5.2. Measurement of Anxiety
Mirror Chamber Test. The mirror chamber consisted of a
wooden chamber having a mirror cube enclosed within it.
Thecontainerboxwas40×40×30.5cm.Animalswereplaced
at the distal cornerof the mirror chamber at the beginning of
the test.
During the 5min test session, the following parameters
were noted: (a) latency to enter the mirror chamber and (b)
average time spent per entry in mirror chamber. An anxio-
genic response was deﬁned as decreased number of entries
and time spent in the mirror chamber [16].
Elevated Plus Maze Test. T h ee l e v a t e dp l u sm a z et e s ti sd e s -
cribed elsewhere. The apparatus comprises of two open arms
(35cm ×5cm)andtwoclosedarms(30cm ×5cm×15cm)
that extend from a common central platform (5cm × 5cm).
The ﬂoor and walls of the closed arms are wooden and
painted black. The entire maze is elevated to height of 50cm
above the ﬂoor level. Mice of 18–22g weight were housed in
pair for 10 days prior to testing in the apparatus. During this
time animals were handled by the investigator on alternate
days to reduce stress; each group consists of 10 animals each.
On the 15th day after immobilization stress, each mouse
was placed in the center of the maze facing one of the open
arms. During a 5-minute test period the following measures
were taken: the number of entries into and time spent in the
open and the closed arms and time spent in central zone and
rearing.Theprocedurewasconductedpreferablyinasound-
attenuated room [16, 17].
2.6. Biochemical Parameters. All the animals were sacriﬁced
bydecapitationonthesamedayimmediatelyafterbehavioral
assessents. The brains were removed, rinsed in isotonic
saline,andweighed.10%(w/v)tissuehomogenateswerepre-
paredwith0.1Mphosphatebuﬀer(pH7.4).Thepostnuclear
fractions were obtained by centrifugation of the homogenate
at 12000×gf o r2 0m i na t4 ◦C.
2.6.1. Lipid Peroxidation Assay. The quantitative measure-
ment of lipid peroxidation in the whole brain was assessed
as per the method of Wills [18].
The amount of malondialdehyde formed was measured
by the reaction with thiobarbituric acid at 532nm using
Perkin Elmer lambda 20 spectrophotometer. The results
were expressed as nanomol of malondialdehyde per mg pro-
tein using the molar extinction coeﬃcient of chromophore
(1.56 × 105M−1 cm−1).
2.6.2. Estimation of Reduced Glutathione. Reduced glu-
tathione (GSH) in the brain was estimated according to the
method of Ellman [19]. A 1.0mL of homogenate was pre-
cipitated with 1.0mL of 4% sulfosalicylic acid by keeping the
mixture at 4◦C for 1h, and samples were immediately centri-
fuged at 12000×gf o r1 5m i na t4 ◦C. The assay mixture con-
tains 0.1mL of supernatant, 2.7mL of phosphate buﬀer of
pH 8.0, and 0.2mL of 0.01M dithio-bis-nitrobenzoic acid
(DTNB). The absorbance of the reaction product was imme-
diately measured at 412nm using Perkin Elmer lambda 20
spectrophotometer. The results were expressed as micromole
GSH per mg protein.
2.6.3. Nitrite Estimation. Nitrite is the stable end product
of nitric oxide (NO) in the living system. Accumulation of
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Figure 1: Illustration of the protocol used for the study.
homogenates by spectrophotometer assay based on Greiss
reagent 15 (1% sulphanilamide/0.1% naphthylethylenedi-
amine dihydrochloride/2.5% phosphoric acid) and incu-
bated at room temperature for 10min to yield a chromo-
phore. Absorbance was measured at 543nm spectrophoto-
metrically.
The nitrite concentration was calculated from a standard
curve using sodium nitrite as standard and expressed as mic-
romolar nitrite per mL homogenate [20].
2.6.4. Protein Estimation. The protein content was measured
according to the method of Lowry et al. using bovine serum
albumin as standard [21].
2.6.5. Catalase Estimation. Catalase activity was assayed by
the method of Luck [22], wherein the breakdown of hydro-
gen peroxide (H2O2) was measured at 240nm. Brieﬂy, the
assay mixture consisted of 3mL of H2O2 in phosphate buﬀer
and0.05mLofsupernatantoftissuehomogenate(10%),and
thechangeinabsorbancewasrecordedat240nm.Theresults
were expressed as micromole H2O2 decomposed per mg of
protein/min.
2.7. Mitochondrial Complex Estimation
2.7.1. Isolation of Rat Brain Mitochondria. Rat brain mito-
chondria were isolated by the method of Berman and Hast-
ings [23]. The striatum regions were homogenized in isola-
tion buﬀer with EGTA (215mM Mannitol, 75mM sucrose,
0.1% BSA, 20mM HEPES, and 1mM EGTA, pH 7.2).
Homogenates were centrifuged at 13,000g for 5min at
4◦C. Pellet was resuspended in isolation buﬀer with EGTA
and spun again at 13,000g for 5min. The resulting super-
natants were transferred to new tubes and topped oﬀ with
isolation buﬀer with EGTA and again spun at 13,000g for
10min. Pellets containing pure mitochondria were resus-
pended in isolation buﬀer without EGTA.
2.7.2. NADH Dehydrogenase Activity. NADH dehydroge-
nase activity was measured spectrophotometrically (UV-
Pharmaspec 1700 Shimadzu, Japan) by the method of King
andHoward[24].Themethodinvolvescatalyticoxidationof
NADH to NAD+ with subsequent reduction of cytochrome
C.
2.7.3. Succinate Dehydrogenase (SDH) Activity. Succinate
Dehydrogenase (SDH) activity was measured spectrophoto-
metrically (UV-Pharmaspec 1700 Shimadzu, Japan) accord-
ing to King [25]. The method involves oxidation of succinate
by an artiﬁcial electron acceptor, potassium ferricyanide.
2.7.4. MTT (Mitochondrial Redox Activity) Assay. The
methodemployedinthepresentstudyisbasedontheinvitro
studies to evaluate mitochondrial redox activity through the
conversion of MTT tetrazolium salt to formazan crystals by
mitochondrial respiratory chain reactions in isolated mito-
chondria by the method of Liu et al. [26]. The absorbance of
the resulting medium was measured by an ELISA reader at
580nm wavelength.
2.7.5. Cytochrome Oxidase Activity. Cytochrome oxidase
activity was assayed according to the method of Sottocasa
et al. in striatal mitochondria [27].
2.8. Statistical Analysis. All the values are expressed as
mean ± SEM. The data were analyzed by using one-way ana-
lysis of variance (ANOVA) followed by Tukey’s test. P<0.05
was considered statistically signiﬁcant.
3. Results
3.1. Behavioral Assessments. The na¨ ıve animals showed con-
sistent and stable locomotor activity and anxiety-like behav-
ior. The 6h acute immobilization stress has signiﬁcantly
reduced the locomotor activity (as indicated by decreased
ambulatory movements) and induced anxiety-like behaviors
(delayed latency to enter the mirror chamber, decreased
number of entries and time spent in the mirror chamber,
and decreased number of entries and time spent in open arm
in elevated plus maze test) as compared to the unstressed
(na¨ ıve) group (P<0.05) (Figures 2, 3, 4, 5,a n d6). Fourteen
days of Hesperidin (50 and 100mg/kg) (P<0.05 and P<
0.01) pretreatment had signiﬁcantly inhibited the anxiety-
like behavior (shortened time latency to enter in mirror
chamber, increased average time spent per entry the mirror
chamber, and increased number of entries and time spent in
open arm in elevated plus maze test) and improved locomo-
tor activity (increased ambulatory movements) as compared
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Figure 2: Eﬀect of Hesperidin on immobilization-stress-induced altered locomotor activity. IS: immobilization stress, Hes: Hesperidin, and
pr: protein, all the values are expressed as mean ± SEM. aP<0.05 compared to na¨ ıve, bP<0.05 compared to control (IS), cP<0.001
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Figure 3: Eﬀect of Hesperidin on immobilization-stress-induced anxiety-like behavior in elevated plus maze test (time spent in open arm).
IS: immobilization stress, Hes: Hesperidin, and pr: protein, all the values are expressed as mean ± SEM. aP<0.05 compared to na¨ ıve, bP<
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Figure 4: Eﬀect of Hesperidin on immobilization-stress-induced
anxiety-like behavior in Elevated plus maze test (No. of entries in
to open arm). IS: immobilization stress, Hes: Hesperidin, and pr:
protein, all the values are expressed as mean ± SEM. aP<0.05
compared to na¨ ıve, bP<0.05 compared to control (IS), cP<0.001
compared to Hesperidin (50), dP<0.05 compared to Hesperidin-
100, and eP<0.05 compared to l-arginine (50).
treatment could not restore the performances of stressed
mice to the levels of naive group.
Pretreatment with l-arginine (50mg/kg, ip), nitric oxide
precursor, produced signiﬁcant anxiety-like behavior on
actophotometer(Figure 2),elevatedplusmaze(Figures3and
4), and mirror chamber tests (Figures 5 and 6)a sc o m p a r e d
to naive (P<0.05). In addition, l-arginine (50mg/kg, i.p.)
treatmenthasreversedtheprotectiveeﬀectofHesperidin(50
and100mg/kg) (in all the behavioural tasks) as compared to
Hesperidinperse(P<0.05).l-NAME(5mg/kg,i.p.),anitric
oxide synthase inhibitor, did not produce any signiﬁcant
eﬀect on actophotometer, elevated plus maze, and mirror
chamber tests as compared to control (IS) (P<0.05). How-
ever,l-NAME(5mg/kg,i.p.)givenincombinationwithHes-
peridin (50 and 100mg/kg) potentiated the protective eﬀect
of Hesperidin (increased ambulatory movements, decreased
latency to enter the mirror chamber, increased number of
entries and time spent in the mirror chamber, and increased
number of entries and time spent in open arm in elevated
plus maze test) as compared to their eﬀect per se (P<0.05)
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Figure 5: Eﬀect of Hesperidin on immobilisation stress induced anxiety-like behavior in mirror chamber test. IS: immobilization stress,
Hes: Hesperidin, and pr: protein, all the values are expressed as mean ± SEM. aP<0.05 compared to na¨ ıve, bP<0.05 compared to control
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Figure 6: Eﬀect of naringin on immobilisation stress induced
anxiety-like behaviour in mirror chamber test (No. of entries).
IS: immobilization stress, Hes: Hesperidin, and pr: protein, all the
values are expressed as mean ± SEM. aP<0.05 compared to na¨ ıve,
bP<0.05 compared to control (IS), cP<0.001 compared to
Hesperidin (50), dP<0.05 compared to Hesperidin-100, and eP<
0.05 compared to l-arginine (50).
In conclusion, pretreatment with Hesperidin (50 and
100mg/kg) oﬀered signiﬁcant protection against acute im-
mobilization-stress-induced behavioral and oxidative dam-
age and possible mechanism of action involves modulation
of nitric oxide pathway.
3.2. Biochemical Measurements. 6h acute immobilization
stress has signiﬁcantly increased the malondialdehyde
(MDA) and nitrite concentration and depleted reduced glu-
tathione (GSH) and catalase activity as compared to unstres-
sed (na¨ ıve) animals. Fourteen days of pretreatment with
Hesperidin (50 and 100mg/kg) (P<0.05 and P<0.01) sig-
niﬁcantly attenuated the rise in MDA and nitrite concentra-
tion and caused restoration of GSH and catalase activity
as compared to the control (immobilization stress) group
(P<0.05) (Table 1).
Treatment with Hesperidin (50 and 100mg/kg) signif-
icantly attenuated elevated lipid peroxidation nitrite activity,
restored reduced glutathione and catalase activity as com-
pared to control (IS) (P<0.05). Pretreatment with l-argi-
nine (50mg/kg, ip) signiﬁcantly increased lipid peroxidation
and nitrite levels as compared to control (IS) (P<0.05)
(Table 1).
A combination of l-arginine (50mg/kg, i.p.) and pre-
treatment with Hesperidin (50 and 100mg/kg) reversed the
neuroprotective eﬀect of Hesperidin (50 and 100mg/kg) on
lipid peroxidation, nitrite activity, reduced glutathione, and
catalase activity as compared to their eﬀect per se (P<0.05)
(Table 1). l-NAME (5mg/kg, ip) per se did not produce any
signiﬁcant eﬀect on oxidative stress parameters as compared
to control (IS) (P<0.05). Furthermore, combination of l-
NAME (5mg/kg, i.p.) pretreatment with Hesperidin (50 and
100mg/kg) caused further attenuation of lipid peroxidation,
nitrite activity and restored the reduced glutathione levels
and catalase activity, which was signiﬁcant as compared to
their eﬀect per se (P<0.05) (Table 1).
3.3. Eﬀect of Hesperidin on Mitochondrial Enzyme Complexes
(I, II, and IV) in Immobilization-Stress-Induced Animals.
There were no signiﬁcant alterations in mitochondrial
enzyme complexes-I, II, IV and mitochondrial redox activity
ofna¨ ıvegroup.However,6hofimmobilizationstresshassig-
niﬁcantly impaired the mitochondrial complexes I (NADH
dehydrogenase), II (succinate dehydrogenase), and IV (cyto-
chrome oxidase) enzyme activity as well as mitochondrial
redox activity in the immobilization stress (IS) control group
ascomparedtothena¨ ıvegroup(Figure 7).Pretreatmentwith
Hesperidin (100mg/kg) (P<0.01) for fourteen days has sig-
niﬁcantly restored the alterations in mitochondrial enzyme
complex activities and mitochondrial redox activity as com-
pared to the IS control group, while pretreatment with
Hesperidin (50mg/kg) (P<0.05) alone has moderately res-
tored the alterations in mitochondrial enzyme complexes
activities and mitochondrial redox activity when compared
to control (IS).
Pretreatment with l-arginine (50mg/kg, ip) signiﬁcantly
increased lipid peroxidation and nitrite levels as compared
to control (IS) (P<0.05). A combination of l-arginine6 ISRN Pharmacology
Table 1: Eﬀects of Hesperidin on immobilization-stress-induced altered oxidative and biochemical parameters in mice (percentage of na¨ ıve
in parentheses).
Treatment Reduced GSH
(µ mole GSH/mg pr)
LPO
(n moles of MDA/mg pr)
Catalase
(µ mole of H2O2/min/mg pr) Nitrite (µg/mL)
Na¨ ıve 0.094 ± 0.004 (100) 0.120 ± 0.003 (100) 0.806 ± 0.005 (100) 261.3 ± 9.4 (100)
Control (IS) 0.014 ± 0.004 (14.89)a 0.634 ± 0.004 (674.46)a 0.141 ± 0.01 (17.49)a 686.4 ± 21.5 (262.68)a
Hes-50 0.038 ± 0.003 (40.42)b 0.462 ± 0.004 (491.48)b 0.421 ± 0.002 (52.23)b 425.8 ± 15.2 (162.95)b
Hes-100 0.061 ± 0.004 (64.89)b,c,e 0.243 ± 0.006 (258.51)b,c,e 0.502 ± 0.001 (62.28)b,c,e 341.6 ± 19.4 (130.73)b,c,e
l-Arginine (50) 0.013 ± 0.005 (13.82)a 0.619 ± 0.007 (658.51)a 0.125 ± 0.003 (15.51)a 694.9 ± 16.2 (265.93)a
l-NAME (5) 0.095 ± 0.002 (101.06)b,c,d,e 0.129 ± 0.001 (137.23)b,c,d,e 0.785 ± 0.001 (97.39)b,c,d,e 260.51 ± 17.5 (119.59)b,c,d,e
l-Arginine (50) + Hes
(50) 0.016 ± 0.003 (17.02) a 0.597 ± 0.003 (635.10)a 0.135 ± 0.005 (16.75)a 668.2 ± 23.2 (255.72)a
l-Arginine (50) + Hes
(100) 0.019 ± 0.004 (20.21)a 0.588 ± 0.006 (625.53)a 0.142 ± 0.003 (17.62)a 657.6 ± 15.5 (251.66)a
l-NAME (5) + Hes
(50) 0.096 ± 0.003 (102.12)b,c,d,e 0.120 ± 0.004 (127.6)b,c,d,e 0.795 ± 0.004 (98.64)b,c,d,e 294.8 ± 14.4 (112.82)b,c,d,e
l-NAME (5) + Hes
(100) 0.108 ± 0.005 (114.89)b,c,d,e 0.109 ± 0.004 (115.9)b,c,d,e 0.816 ± 0.003 (101.24)b,c,d,e,f 272.2 ± 19.5 (104.17)b,c,d,e
IS: immobilization stress, Hes: Hesperidin, and pr: protein, all the values are expressed as mean ± SEM. aP< 0.05 compared to na¨ ıve, bP<0.05 compared to
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Figure 7: Eﬀect of Hesperidin on immobilization stress induced mitochondrial dysfunction in mice (% na¨ ıve). IS: immobilization stress,
Hes: Hesperidin, and pr: protein, all the values are expressed as mean ± SEM (% of na¨ ıve group), aP<0.05 compared to na¨ ıve, bP<0.05
compared to control (IS), cP<0.001 compared to Hesperidin (50), dP<0.05 compared to Hesperidin-100, and eP<0.05 compared to
l-arginine (50).
(50mg/kg, i.p.) pretreatment with Hesperidin (50 and
100mg/kg) reversed the protective eﬀect of Hesperidin (50
and 100mg/kg) on mitochondrial enzyme complex activities
and mitochondrial redox activity as compared to their eﬀect
per se (P<0.05). l-NAME (5mg/kg, ip) per se did not
produce any signiﬁcant eﬀect on normal mitochondrial
functions as compared to control (IS) (P<0.05). Further-
more, combination of l-NAME (5mg/kg, i.p.) pretreatment
with Hesperidin (50 and 100mg/kg) caused further restora-
tion of alterations in mitochondrial enzyme complex activi-
ties and mitochondrial redox activity, which was signiﬁcant
as compared to their eﬀect per se (P<0.05).ISRN Pharmacology 7
4. Discussion
Stress is a physical and/or environmental and/or psycho-
logical stimulus that is capable of altering the physiological
homeostasis of the body, and hence coping up with such
stress condition makes it as a crucial determinant in health
and disease [28].
Stress activates hypothalamus-pituitary-adrenal axis
(HPA) and also causes changes in catecholamine levels and
thereby inﬂuences several neurological functions at both
central and peripheral levels. Any kind of stress inﬂuences
brainfunctionsbycausinglong-termchangesinthemultiple
neural systems, which leads to various neurodegenerative
disorders [29]. Exposure to chronic immobilization stress in
animals and psychological stress in human has implicated
pathophysiology of anxiety and mood disorders [30]. Acute
immobilization stress has been reported to inﬂuence motor
activity, anxiety-like behavior, and depression-like behaviors
in the animals [31]. In the present study, 6h immobilization
stress caused signiﬁcant anxiety-like behavior and impaired
motor activity, indicating stress-induced neurobehavioral
alterations and neurobehavioral alterations due to acute and
chronicstresshasalreadybeenreportedintheliterature[31].
In the present study observed behavioral changes might be
due to alteration in the brain regions controlling motor
activity and anxiety-like behavior, while impaired motor
activity could be due to stress-induced depression.
In the present study, Hesperidin (50 and 100mg/kg, p.o.)
oﬀered signiﬁcant protection against immobilization stress
induced neurobehavioral alterations (locomotor activity and
anxiety-like behavior) and oxidative damage to the brain,
suggesting its neuroprotective eﬀect against stressful condi-
tions.
Immobilization stress causes drastic increase in the pro-
duction of reactive oxygen species and consequent oxidative
damage with a proportionate decrease in in vivo antioxidant
defense [32]. Oxidative stress causes cellular damage and
accelerates neurodegeneration by inducing the reactive oxy-
gen species (ROS) that oxidize vital cellular components
such as lipids, proteins, and DNA [33]. In the present study,
6h immobilized stress caused signiﬁcant oxidative dam-
age as indicated by the rise in lipid peroxidation, nitrite
concentration and depleted reduced GSH and catalase activ-
ity. Pretreatment with Hesperidin (50 and 100mg/kg) has
signiﬁcantly attenuated the lipid peroxidation and nitrite
concentration and restored GSH and catalase activity sug-
gesting its antioxidant-like eﬀect. Supporting our study, a
clinical trial also indicated raised level of MDA in patients
with aﬀective disorders [34]. Besides, it is been demonstra-
ted that immobilization stress induces expression of the in-
ducible isoform of NO synthase (NOS-2) in rat brain [35]
andleadingtoformationoflargeamountofnitrogenreactive
species that may account for the oxidation of cellular com-
ponents [36].
In accordance with the above ﬁndings, in the present
study, Hesperidin elevated the antioxidant enzyme defense
system against immobilization stress-induced oxidative
damage. The possible mechanism behind the protective ef-
fect of Hesperidin is inhibition of NO synthesis in the brain.
Mitochondria are considered as a major source of ROS,
which include superoxide anion (
•O2), H2O2, and the hyd-
roxyl free radical (
•OH). The evidence suggests that oxida-
tive stress-induced damage to mitochondria is a major cause
of brain cell death [37]. Damage in various mitochondrial
complexes was measured in terms of respiratory enzyme oxi-
dative properties and our ﬁndings in the present study are
in accordance with the literature reports. Major dysfunctions
in complexes I and II and minor dysfunction in complexes
III and IV were observed when compared to their respective
control groups.
Hesperidin (50 and 100mg/kg) pretreatment has signiﬁ-
cantly restored the mitochondrial enzyme activity suggesting
its role in mitochondrial enzyme functions. Further, l-argi-
nine pretreatment with Hesperidin (50 and 100mg/kg)
caused reversal of Hesperidin protective eﬀect (impairment
of mitochondrial enzyme complex), while, l-NAME pre-
treatment with Hesperidin caused potentiation of its pro-
tective eﬀect (restoration of mitochondrial enzyme activity),
which further conﬁrms the involvement of nitric oxide
mechanism.
5. Conclusion
The ﬁndings of the present study suggest that Hesperidin (50
and 100mg/kg) is a bioﬂavonoid found to ameliorate
the immobilization-stress-induced oxidative-nitrergic stress,
biochemical alterations, mitochondrial dysfunction, and
associated neurobehavioral alterations in mice and also sug-
gest the involvement of nitrergic pathway in the protective
eﬀect of Hesperidin against immobilization-stress-induced
neurobehavioral alterations.
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